Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Bacteremia or Pneumonia
Sunish Shah, Ellen G Kline, Ghady Haidar, Kevin M Squires, Jason M. Pogue, Erin K. McCreary, Justin Ludwig, Lloyd Clarke, Madison Stellfox, Daria Van Tyne, Ryan K. Shields
Abstract
Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as ≥4-fold increased MIC) than those treated with ceftolozane-tazobactam (40% vs 10%; P = .002). Ceftazidime-avibactam resistance was associated with new mutations in ampC and efflux regulatory pathways.
Topics & Concepts
Ceftazidime/avibactamMedicinePseudomonas aeruginosaBacteremiaPneumoniaCeftazidimeMicrobiologyHospital-acquired pneumoniaTazobactamInternal medicineAntibioticsAntibiotic resistanceImipenemBacteriaBiologyGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyUrinary Tract Infections Management